The advanced therapeutics company Integra Therapeutics, member of CATALONIA.HEALTH, and the Lithuanian company Caszyme have announced a license agreement for the use of Cas12I, Caszyme’s innovative nucleoases, to develop safer and more efficient gene and cell therapies.
According to the terms of the agreement, Integra Therapeutics will incorporate the genomic editor Cas12l into its FiCAT 2.0 (Find and Cut-And-Transfer) genetic writing platform, after the success of live and ex-live studies that have launched very positive results in terms of safety and functionality in human cells.
Avencia Sánchez-Mejías, CEO and co-founder of Integra Therapeutics, points out that "this agreement with Caszyme reaffirms the constant evolution of our preclinical regulatory gene writing technology and also highlights the success of the transnational project funded by the European Commission that we started in 2022, through Eurostars, in support of the most innovative SMEs in Europe".
Marc Güell, CSO and co-founder of Integra Therapeutics, explains, “The integration of Caszyme nucleoases into our FiCAT 2.0 platform reinforces Integra Therapeutics’ mission to generate the highest quality gene and cell therapy products for the treatment of a wide variety of genetic and oncological diseases. FiCAT 2.0 will be differentiated in the market because it will provide improved precision and efficiency”.
Comments